肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
3期
182-184,187
,共4页
高彦军%刘红耀%赵少成%刘春%马志方%胡操阳%张华屏%武能新%任连生
高彥軍%劉紅耀%趙少成%劉春%馬誌方%鬍操暘%張華屏%武能新%任連生
고언군%류홍요%조소성%류춘%마지방%호조양%장화병%무능신%임련생
膀胱肿瘤%模型,动物%多药耐药
膀胱腫瘤%模型,動物%多藥耐藥
방광종류%모형,동물%다약내약
Urinary bladder neoplasms%Models,animal%Multidrug resistance
目的 建立T24-多柔比星(ADM)模拟人类原位膀胱癌多药耐药模型并行耐药性检测.方法 采用细胞移植法将T24-ADM耐药株及T24细胞敏感株移植到两组裸鼠膀胱后定期观察其一般情况.28d后处死裸鼠,称成瘤膀胱质量、测体积,行组织病理学和细胞学检测,反转录聚合酶链反应(RT-PCR)检测多药耐药基因-1(MDR-1)的表达,MTT法测瘤组织制成的细胞悬液耐药性.结果 T24-ADM组及T24组裸鼠膀胱的成瘤率分别为80%(8/10)和90%(9/10),成瘤膀胱平均体质量和体积分别为(0.8±0.3)g、(1.0±0.5)g、(875±158)mm3、(903±192)mm3,组间比较差异均无统计学意义(t=1.332和t=1.215,P>0.05).组织病理学:T24-ADM组4只出现右肾增大,T24组2只出现右肾增大,1.0 cm×1.8 cm,色暗灰到暗红.膀胱肿瘤组织切片细胞结构排列较乱,形态不规则,向肌层不同深度浸润,未突破浆膜层,两组间差异不明显.RT-PCR测MDR-1表达两组间差异有统计学意义(t=3.612,P<0.01).MTT检测T24-ADM组裸鼠肿瘤细胞较T24组对ADM有明显的耐药性,差异有统计学意义(F=412.107,P<0.01),且对其他几种药物也有耐药性,差异有统计学意义(P<0.05).结论 细胞移植法成功建立了T24-ADM原位膀胱癌耐药模型,并具有多药耐药特性.
目的 建立T24-多柔比星(ADM)模擬人類原位膀胱癌多藥耐藥模型併行耐藥性檢測.方法 採用細胞移植法將T24-ADM耐藥株及T24細胞敏感株移植到兩組裸鼠膀胱後定期觀察其一般情況.28d後處死裸鼠,稱成瘤膀胱質量、測體積,行組織病理學和細胞學檢測,反轉錄聚閤酶鏈反應(RT-PCR)檢測多藥耐藥基因-1(MDR-1)的錶達,MTT法測瘤組織製成的細胞懸液耐藥性.結果 T24-ADM組及T24組裸鼠膀胱的成瘤率分彆為80%(8/10)和90%(9/10),成瘤膀胱平均體質量和體積分彆為(0.8±0.3)g、(1.0±0.5)g、(875±158)mm3、(903±192)mm3,組間比較差異均無統計學意義(t=1.332和t=1.215,P>0.05).組織病理學:T24-ADM組4隻齣現右腎增大,T24組2隻齣現右腎增大,1.0 cm×1.8 cm,色暗灰到暗紅.膀胱腫瘤組織切片細胞結構排列較亂,形態不規則,嚮肌層不同深度浸潤,未突破漿膜層,兩組間差異不明顯.RT-PCR測MDR-1錶達兩組間差異有統計學意義(t=3.612,P<0.01).MTT檢測T24-ADM組裸鼠腫瘤細胞較T24組對ADM有明顯的耐藥性,差異有統計學意義(F=412.107,P<0.01),且對其他幾種藥物也有耐藥性,差異有統計學意義(P<0.05).結論 細胞移植法成功建立瞭T24-ADM原位膀胱癌耐藥模型,併具有多藥耐藥特性.
목적 건립T24-다유비성(ADM)모의인류원위방광암다약내약모형병행내약성검측.방법 채용세포이식법장T24-ADM내약주급T24세포민감주이식도량조라서방광후정기관찰기일반정황.28d후처사라서,칭성류방광질량、측체적,행조직병이학화세포학검측,반전록취합매련반응(RT-PCR)검측다약내약기인-1(MDR-1)적표체,MTT법측류조직제성적세포현액내약성.결과 T24-ADM조급T24조라서방광적성류솔분별위80%(8/10)화90%(9/10),성류방광평균체질량화체적분별위(0.8±0.3)g、(1.0±0.5)g、(875±158)mm3、(903±192)mm3,조간비교차이균무통계학의의(t=1.332화t=1.215,P>0.05).조직병이학:T24-ADM조4지출현우신증대,T24조2지출현우신증대,1.0 cm×1.8 cm,색암회도암홍.방광종류조직절편세포결구배렬교란,형태불규칙,향기층불동심도침윤,미돌파장막층,량조간차이불명현.RT-PCR측MDR-1표체량조간차이유통계학의의(t=3.612,P<0.01).MTT검측T24-ADM조라서종류세포교T24조대ADM유명현적내약성,차이유통계학의의(F=412.107,P<0.01),차대기타궤충약물야유내약성,차이유통계학의의(P<0.05).결론 세포이식법성공건립료T24-ADM원위방광암내약모형,병구유다약내약특성.
Objective To establish the orthotopic bladder cancer model of multidrug resistance as the human' s, and detect its resistance condition. Methods Two groups of nude rats 4-6 weeks of age were inculated with 1×107 cell of T24 or T24-ADM, following with observation and putting down their meat, drink,mental condition, urine and abdominal mass growth. Animals were sacrificed after 4 weeks later, then their bladder were weighted and measured, histopathologic assessment was performed,mdr1 was detected by PCR,and cells from the bladder tumors were detected of multidrug resistence by MTT. Results Group of nude rats inculated with T24-ADM generated tumors about 80 % (8/10), the one inculated with T24 was 90 % (9/10)and about 2-3 days early. The blank group had no rats emerge tumors in bladder mucosa at all. Bladder weight and volume: (0.8±0.3) g, (1.0±0.5) g, (875±158) mm3, (903±192) mm3, difference between the two groups had no significant (t = 1.332 and t = 1.215, P>0.05). Histopathologic detection: The two groups of bladder cancer tissue biopsies can be seen more chaotic arrangement of cell structure, cell body shape is irregular, to the depth of myometrial invasion in different without breaking the film. Between the two groups there were no significantly differences. PCR detection of mdr1 expression differences between the two groups was significant (t = 3.612, P <0.01). Cytological detection of drug-resistant cell volume is slightly larger, and no significant difference in morphology. MTT detection: cells from the inculated T24-ADM mice bladder tumor were more resistance to ADM than the ones from the inculated T24 mice bladder tumor (F = 412.107, P<0.01), and for several other drugs were also resistant. Conclusion Cell transplantation was successfully used to establish bladder cancer model in situ of T24-ADM, and with multi-drug resistance characteristics. The model laid the foundation for further multi-drug resistance research of bladder cancer.